NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) have been given a consensus rating of “Moderate Buy” by the five analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $8.50.

Several research analysts have issued reports on the company. Wall Street Zen upgraded NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. D. Boral Capital reiterated a “buy” rating and issued a $14.00 price target on shares of NeuroSense Therapeutics in a report on Wednesday, April 8th. Finally, Roth Mkm initiated coverage on NeuroSense Therapeutics in a report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price target on the stock.

Institutional Investors Weigh In On NeuroSense Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NRSN. Two Sigma Investments LP bought a new position in NeuroSense Therapeutics during the 3rd quarter valued at $26,000. Jane Street Group LLC bought a new position in NeuroSense Therapeutics during the 2nd quarter valued at $54,000. Yorkville Advisors Global LP bought a new position in NeuroSense Therapeutics during the 4th quarter valued at $77,000. Finally, Squarepoint Ops LLC lifted its stake in NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares in the last quarter. 1.04% of the stock is owned by hedge funds and other institutional investors.

NeuroSense Therapeutics Price Performance

NASDAQ NRSN opened at $0.81 on Wednesday. The business has a 50 day simple moving average of $0.79 and a 200 day simple moving average of $0.93. NeuroSense Therapeutics has a one year low of $0.63 and a one year high of $2.60. The stock has a market capitalization of $26.34 million, a P/E ratio of -1.50 and a beta of 1.70.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.